Navigation Links
Xcat 100

ProductsXcat 100
Company Kubtec
Item Xcat 100
Features 
Description The desk-top XCAT 100 X-Ray System from KUBTEC is a dual capability system with the ability to provide two and three dimensional representation of the specimen under test. While the XCAT series provides volumetric reconstruction of specimen X-ray images, the micro focus source also allows the system to provide high level of detail in standard 2D images. The 100 mm x 100 mm digital detector provides image resolution at 12 bits and 10 lp/mm. The compact size and shielding allow the unit to be easily located in most environments. The fast state-of-the-art CT reconstruction software and parallel processing capability enables the user to obtain high quality images from all viewing angles in a relatively short period of time.
Info Kubtec
Customer Service: (203) 364-8544
Web site: http://www.kubtec.com

Related medicine products :

1. GeneXpert System
2. Xpert 80
3. Xpert GBS
4. Clinical Xpert™ PDA Medical Reference and Decision-Support Tool
TAG: Xcat
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products:
(Date:5/16/2008)...afety and efficacy of first FDA-approved nebulized... to severe COPD -, NAPA, Calif., May 16 /PRNewswi...al data presentations will be given at the Interna... (ATS) on May 20, 2008 at the,Metro Toronto Conven...effects on dyspnea and other COPD symptoms of usin...
(Date:5/16/2008)...dding a second monoclonal antibody drug to chemoth...ge B-cell lymphoma, according to Mayo Clinic resea...ment Group (NCCTG) ( http://ncctg.mayo.edu/ ). Res... as part of the 44th Annual Meeting of the America...ound that 95 percent of patients responded to trea...
(Date:5/16/2008)...creased use of MRI before surgeries, researchers r...s) -- After years of declining rates, the number o...er is on the rise again, the Mayo Clinic now repor...ge of magnetic resonance imaging (MRI) before surg...o present their findings May 31 at the American So...
(Date:5/16/2008)... 16 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.,(Na...resentations evaluating,the Company,s lead product...ican Society of Clinical Oncology (ASCO) annual me...improved survival for patients with metastatic,ost...ts with non-small lung,cancer treated with IDM-210...
Breaking Medicine News(10 mins):Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 2Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 3Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 4Health News:Clinical Trial Data for Perforomist(TM) Inhalation Solution to be Presented at ATS on May 20, 2008 5Health News:Adding epratuzumab to standard therapy 2Health News:Mastectomies on the Increase 2Health News:Mastectomies on the Increase 3Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 2Health News:IDM Pharma Announces Presentations at 44th American Society of Clinical Oncology Annual Meeting 3
...marital arguments can have devasting consequences ...cing age //. The National Institute on Aging has c...tal Quality and Health Over the Life Course' which...s can contribute to stress. The stress can infact...
...-Gooden, a clinical psychologist and author, a lot...emotional overeater’s who try to mask their depres...rican women generally do not seek treatment for th...igious community and family members don't recogniz...
...ent that lifted up faces and brought cheer to the ...the tabs for three types of obesity surgery, in c...blems. // But the catch is that, only surgeries p...rgeons or the American Society of Bariatric Surger...
...vices Group Inc. has announced that it will be mak...h prostate cancer//. This move comes, as the survi...etter chemotherapy as well as early diagnosis and ...plans at standard rates "to men 60 and older who h...
Other Medicine News:Health News:Marriage Squabbles Can Make You Sick 2Health News:African-American Women Need To Seek Advice On depression 2
(Date:5/16/2008)...TAN, N.J., May 16 /- Veridex, LLC ann...ratory Corporation of America Holdings,(LabCorp), ...est for,prostate cancer. The new assay uses the bi...ate cancer, detecting the methylation of the gene,...occurs primarily in,cancer. Veridex is developing ...
(Date:5/15/2008)... Results Confirm Efficacy for Population Most Affe...lif., May 16 /-,Bayer Healt...ls, Inc.,(Nasdaq: ONXX ) today announced that Nex... overall survival by 47.3 percent (HR=0.68;,p-valu...th advanced,hepatocellular carcinoma (HCC), or pri...
(Date:5/15/2008)...FRANCISCO, May 15 /- Mediva...ata from an ongoing Phase 1-2 clinical,trial of it...l be presented,in an oral presentation at the 44th...al Meeting in Chicago., Session title: New Targ... Session date and time: Monday, June 2 at 11:30 a....
(Date:5/15/2008)...II Data Presented at ASCO Showed Acceptable Tolera...Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N.J., M...rapeutic agent eribulin mesylate (E7389) demonstra... women with locally advanced or metastatic,breast ...se II clinical,trial. The study also suggests that...
Breaking Medicine Technology:Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3First wind turbines on Galapagos Islands will halve diesel imports reduce risk of future oil spills 2259 1First wind turbines on Galapagos Islands will halve diesel imports reduce risk of future oil spills 2259 2First wind turbines on Galapagos Islands will halve diesel imports reduce risk of future oil spills 2259 3First wind turbines on Galapagos Islands will halve diesel imports reduce risk of future oil spills 2259 45W Public Relations Hosts Exclusive Beauty 26 Wellness Industry Event 12165 15W Public Relations Hosts Exclusive Beauty 26 Wellness Industry Event 12165 2Is transgenic cotton more profitable 3F 2258 1Is transgenic cotton more profitable 3F 2258 2Congressman Buchanan Tours Florida Clinical Laboratory 3B Learns Vital Role in Patient Care 12159 1Congressman Buchanan Tours Florida Clinical Laboratory 3B Learns Vital Role in Patient Care 12159 2
...LBERG, Germany, 11 July 2007 – On 23 July SY...nical phase IIa study for,AX200 (AXIS-study)., AX2... most,advanced drug candidate in SYGNIS’ pro...show safety and tolerability of,AX200 in acute str...pected to provide information for the further clin...
...TLE, July 11, 2007 /PRNewswire-FirstCall/ -- On We...p.m. Eastern/10:30 p.m.,Central European Time memb...team will host a conference call to discuss today,... II/III RAPID trial,comparing CHOP-R to CPOP-R, in...n standard CHOP-R, in first-line treatment of pati...
Other Medicine Technology:Sygnis Pharma AG announces date for presentation of clinical,results 2Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2